Association Patterns in Open Data to Explore Ciprofloxacin Adverse Events

Area of Science:

• Pharmacovigilance
• Drug Safety
• Data Mining in Healthcare

Background:

• Ciprofloxacin is a key antibiotic for bacterial infections, which cause significant global morbidity and mortality.
• Analyzing adverse events is crucial for understanding drug safety profiles.
• The U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (AERS) database is a valuable resource for drug safety surveillance.

Purpose of the Study:

• To uncover novel associations between ciprofloxacin adverse events, patient demographics, and event outcomes.
• To identify patterns in ciprofloxacin-related adverse events using a large-scale database.
• To provide data-driven insights for pharmaceutical research and clinical decision-making.

Main Methods:

• Extracted and analyzed 6,531 reports from the FDA AERS database concerning ciprofloxacin.
• Performed statistical analysis to determine frequent adverse events and outcomes, stratified by age and gender.
• Applied the Apriori algorithm to discover association rules among adverse events, validating findings with classical data mining techniques.

Main Results:

• Pyrexia, pain, diarrhea, and anxiety were the most frequent adverse events reported with ciprofloxacin.
• Hospitalization was the most common adverse event outcome.
• Significant age and gender-specific differences in adverse event occurrence were observed, with preschool, middle-aged, and elderly groups reporting more events.
• The Apriori algorithm revealed associations between ciprofloxacin and psychiatric disorders, particularly in specific gender groups.

Conclusions:

• The FDA AERS database is instrumental in identifying new or previously unrecognized adverse drug events.
• The study's findings offer critical information for medical researchers and pharmaceutical decision-makers regarding ciprofloxacin safety.
• Understanding demographic associations with adverse events can inform targeted drug safety monitoring and patient management strategies.